This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria.
👑 ¿Será suficiente una depleción más profunda de células B para reclamar el trono?
📖 Revisa el más reciente resumen visual elaborado por la Dra Divya Bajpai
